PMID- 31128279
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
VI  - 207
DP  - 2019 Oct
TI  - iNKT cells and hematopoietic stem cell transplantation: Two-phase activation of 
      iNKT cells may improve outcome.
PG  - 43-48
LID - S1521-6616(19)30070-1 [pii]
LID - 10.1016/j.clim.2019.05.011 [doi]
AB  - Invariant natural killer T cells (iNKT) produce large amounts of different 
      cytokines which can influence differentiation, polarization and activation of 
      immune cells, particularly NK and T cells. iNKT have been shown to suppress GvHD 
      and promote anti-tumor and anti-pathogen immunity. There are highly specific and 
      safe synthetic ligands such as alpha-galactosylceramide (alpha-GalCer) and C20:2 
      which activate iNKT cells toward relatively Th1 and Th2 pathways, respectively. 
      Bone marrow transplantation (BMT) or 'hematopoietic stem cell transplantation' 
      (HSCT) is effective for leukemia and lymphoma through 'graft-versus-leukemia' 
      (GVL) immunity. However, frequent serious complications include 
      graft-versus-host-disease (GVHD), opportunistic infections and relapse. Both GVHD 
      and GVL are mediated by T cells. Manipulating iNKT by different lipid analogues 
      in early and late phases after transplantation may suppress GVHD and graft 
      rejection and enhance GVL effect, as well as resistance to opportunistic 
      infections and so, could be a novel and effective strategy for improving HSCT 
      outcome.
CI  - Copyright (c) 2019. Published by Elsevier Inc.
FAU - Fereidouni, Mohammad
AU  - Fereidouni M
AD  - Cellular and Molecular Research Center, Birjand University of Medical Sciences, 
      Birjand, Iran; Asthma, Allergy & Immunology Research Center, Birjand University 
      of Medical Sciences, Birjand, Iran. Electronic address: M.fereidouni@bums.ac.ir.
FAU - Derakhshani, Afshin
AU  - Derakhshani A
AD  - Student Research Committee, Birjand University of Medical Sciences, Birjand, 
      Iran; Cellular and Molecular Research Center, Birjand University of Medical 
      Sciences, Birjand, Iran; Asthma, Allergy & Immunology Research Center, Birjand 
      University of Medical Sciences, Birjand, Iran.
FAU - Exley, Mark A
AU  - Exley MA
AD  - Division of Gastroenterology, Endoscopy, and Hepatology, Brigham and Women's 
      Hospital and Harvard Medical School, Boston, MA, USA; Manchester Collaborative 
      Centre for Inflammation Research, University of Manchester, UK. Electronic 
      address: mexley@partners.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190523
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
SB  - IM
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunomodulation
MH  - Immunotherapy
MH  - *Natural Killer T-Cells/immunology
EDAT- 2019/05/28 06:00
MHDA- 2020/05/19 06:00
CRDT- 2019/05/26 06:00
PHST- 2019/02/06 00:00 [received]
PHST- 2019/05/16 00:00 [revised]
PHST- 2019/05/17 00:00 [accepted]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
PHST- 2019/05/26 06:00 [entrez]
AID - S1521-6616(19)30070-1 [pii]
AID - 10.1016/j.clim.2019.05.011 [doi]
PST - ppublish
SO  - Clin Immunol. 2019 Oct;207:43-48. doi: 10.1016/j.clim.2019.05.011. Epub 2019 May 
      23.